Rossi - Stein - powerhouses - Looking for $20?
CytoGenix Scientists Findings to be Published in Cancer Journal
6/29/2006 11:50:00 AM EST
BIOWIRE
CytoGenix, Inc. (OTCBB:CYGX) Dr. Yin Chen, CytoGenix Chief Scientific Officer; Ms. Harilyn McMicken, CytoGenix, Laboratory Director; Dr. Cy Stein, Professor of Medicine at Albert Einstein School of Medicine; and Dr. John Rossi, Chairman and Professor in the Division of Molecular Biology, City of Hope have collaborated in a study that has been accepted for publication in the peer-reviewed journal Clinical Cancer Research. Drs. Stein and Rossi are directors of the company and members of its scientific advisory board.
The paper titled "The Function of Bcl-2 Protein in 518A2 Melanoma Cells In Vivo Differs Dramatically from its In Vitro Role" presents data from experiments performed on mice xenografted with human melanoma tumors and demonstrates that Bcl-2 protein could be an important therapeutic target in reducing or regressing tumors.
Dr. Cy Stein, the lead investigator, states, "This study helps to validate the use of the CytoGenix proprietary ssDNA technology in settings where permanent down-regulation of gene expression is needed, leading in this case, to unexpected and dramatic results."
Dr. Yin Chen states, "This is a significant step forward for CytoGenix because it is the first time that the company's ssDNA technology has been shown to be effective an in vivo cancer model."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix is the recipient of the 2006 Frost & Sullivan Technology Innovation award for biotechnology processing. CytoGenix currently has one issued US patent and 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.
For more information on the Frost & Sullivan Technology Innovation award visit the Frost site: frost.com
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at cytogenix.com .
CONTACT:
CytoGenix, Inc., Houston Frank Vazquez, 713-789-0070
genengnews.com
CYGX.OB Quote:
finance.yahoo.com |
